Navigation Links
Anesiva Announces Merger With Arcion Therapeutics Will Not be Completed
Date:12/31/2009

SOUTH SAN FRANCISCO, Dec. 31 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) announced today that it was unable to satisfy the closing conditions set forth in the Agreement and Plan of Merger, dated August 4, 2009, among Anesiva, Arca Acquisition Corporation, a wholly-owned subsidiary of Anesiva, Arcion Therapeutics, Inc. ("Arcion") and, with respect to Articles V and IX only of the agreement, each of the Arcion stockholders listed on Schedule I thereto (the "Merger Agreement"). The Company intends to immediately cease operations and to file a petition for relief under the Bankruptcy Code.

About Anesiva

Anesiva seeks to be a leader in the development and commercialization of novel pharmaceutical products for pain management. Anesiva's lead product candidate is Adlea, a novel small molecule formulation of capsaicin that is currently in development for the management of acute pain following orthopedic surgeries. Adlea has been shown in clinical trials to provide extended pain relief after only a single administration in multiple indications for site-specific, acute and chronic, moderate-to-severe pain.

Forward-Looking Statements

Except for historical information, this press release may be deemed to contain "forward-looking" statements. Words such as "seek" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include statements regarding forecasts of product development and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from those referred to in the forward-looking statements. Such risks include, but are not limited to, the risk of whether certain market segments grow as anticipated; clinical trial results; the competitive environment in the biotechnology industry; and whether Anesiva can successfully develop new products and the degree to which these gain market acceptance as well as other risks detailed from time to time in Anesiva's filings with the Securities and Exchange Commission ("SEC"), including Anesiva's most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2008, its Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K as filed with the SEC. Anesiva expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

http://www.anesiva.com

SOURCE Anesiva, Inc.

RELATED LINKS
http://www.anesiva.com

'/>"/>

SOURCE Anesiva, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lees Pharmaceuticals
2. Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger
3. Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing
4. Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
5. Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
6. Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company
7. Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery
8. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
9. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
10. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
11. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... --> --> ... Packaging Equipment Market by Package Type (Blister, Strip, Bottle, ... Type (Tablet, Powder, Cream, Syrup, Aseptic Liquid, Aerosol) - ... market during the forecast period of 2015 to 2020. ... of 6.9% during the forecast period to reach USD ...
(Date:2/10/2016)... 10, 2016 The campaign aims to ... 5 years reach the milestone of their 5 th birthday ... ensure 2,50,532 children between the ages of 2 - 5 years ... --> The campaign aims to ensure ... reach the milestone of their 5 th birthday   ...
(Date:2/9/2016)... , Feb. 9, 2016  Insulet Corporation (NASDAQ: PODD ... insulin pump technology with its OmniPod ® ... Lemoine has been appointed to Insulet,s Board of Directors. ... directors, eight of whom are independent. --> ... of audit and finance experience and a deep knowledge of ...
Breaking Medicine Technology:
(Date:2/10/2016)... AZ (PRWEB) , ... February 10, 2016 , ... Ongoing ... the Aging Life Care Association™ (ALCA) to conduct a survey that takes a closer ... experts released today illustrates the prevalence and causes of TBI among the aging population, ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... AxoGen, Inc. ... will report results for the fourth quarter and full year ended December 31, 2015 ... a conference call and webcast for the investment community following the release at 4:30 ...
(Date:2/10/2016)... ... ... For additional information contact Phyllis Strupp 480-488-5858 , Brain improves with age, ... Guide to Brain Training" by award-winning author Phyllis Strupp explains how brain ... 16, 2016. A free review copy is available to the media at NetGalley ...
(Date:2/10/2016)... ... February 10, 2016 , ... IDEX Health & Science, LLC ... steel (PLS) columns combine the strength of traditional stainless steel with the chemical ... samples while operating at ultra-high pressures of 20,000 psi. The higher operating pressures ...
(Date:2/10/2016)... , ... February 10, 2016 , ... The recreational use ... enthusiasts in the state still face a lot of restrictions as to where they ... intended for private, personal use” and that cannabis “may not be consumed openly or ...
Breaking Medicine News(10 mins):